In parallel to the higher number, an increased production of IL-10 and TGF-β1, and an overexpression of the immunosuppressive molecule CTLA-4 characterize Tregs from CLL patients compared to controls (104, 121, 123). This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.